

Engagement Report for Clinical Commissioning Policies

Unique Reference Number	F06X04
Policy Title	Plasma-derived C1-esterase inhibitor for Prophylactic treatment of hereditary angioedema (HAE) types I and II
Accountable Commissioner	Jane Pearson-Moore
Clinical Reference Group	Allergy and Immunology
Which stakeholders were contacted to be involved in policy development?	Allergy and immunology CRG membership and all registered stakeholders
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	Representatives of relevant Royal College or Professional Societies were contacted for Stakeholder Testing as part of the CRG
Which stakeholders have actually been involved?	All of the key stakeholders listed above were invited to comment
Explain reason if there is any difference from previous question	Not applicable
Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?	None
How have the stakeholders been involved? What engagement methods have been used?	<p>The draft policy was circulated to the full membership of the CRG and registered stakeholders for two weeks for their views, both to establish whether any amendments to the policy are required, and to understand from their perspective what the key questions to ask at consultation might be.</p> <p>Four responses were received: two from CRG members (one from UKPIN and one from HAE UK) and two from CRG-registered stakeholders (both represented pharmaceutical companies). Responses included requests for some minor edits to the policy proposition, clarification on the network arrangements, consideration of additional data and reconsideration of the minimum number of training sessions required to teach self-administration of medication.</p>

FOR PUBLIC CONSULTATION ONLY

What has happened or changed as a result of their input?	Stakeholders were invited to comment. Minor updates were made to the policy proposition in response to comments received. No change was made to the evidence review. Additional stakeholders identified (UKPIN, HAE UK, BSI and BSACI) will be invited to comment as part of the public consultation.
How have stakeholders been informed of progress with policy development as a result of their input?	This engagement report, along with the updated policy proposition will be circulated as part of the public consultation. Stakeholders will be notified and invited to comment further.
What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?	Public consultation for a period of 30 days as supported by stakeholders